Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 6, 2014, Pages 512-529

  Davis, Justin ^a   Moylan, Steven ^a   Harvey, Brian H ^b   Maes, Michael ^a,c   Berk, Michael ^a,d,e  

^a DEAKIN UNIVERSITY   (Australia)

^b NORTH WEST UNIVERSITY   (South Africa)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Epigenetics; Inflammation; Mitochondrial dysfunction; Neuroprogression; NMDA; Oxidative stress; Schizophrenia; TRYCATs

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCYSTEINE; ACUTE PHASE PROTEIN; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; COMPLEMENT FACTOR; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MEMBRANE PROTEIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUNSATURATED FATTY ACID; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; SECRETORY PROTEIN; SUPEROXIDE DISMUTASE; THIOREDOXIN PEROXIDASE; THORIUM; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; NEUROLEPTIC AGENT; CELECOXIB; DNA METHYLTRANSFERASE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; PARVALBUMIN; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SOLUBLE INTERLEUKIN 2 RECEPTOR; TRYPTOPHAN CATABOLITE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANTERIOR CINGULATE; ANTERIOR COMMISSURE; CAPSULA INTERNA; CAUDATE NUCLEUS; DENDRITIC SPINE; DIET SUPPLEMENTATION; DISEASE COURSE; EMBRYO DEVELOPMENT; EPIGENETICS; FRONTAL LOBE; HIPPOCAMPUS; HUMAN; NONHUMAN; PATHOGENESIS; POSTERIOR CINGULATE; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUPERIOR FRONTAL GYRUS; SUPERIOR TEMPORAL GYRUS; SURFACE PROPERTY; TEMPORAL LOBE; VOXEL BASED MORPHOMETRY; WHITE MATTER; BRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; ADJUVANT THERAPY; BIOCHEMISTRY; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GRAY MATTER; GYNECOLOGIC DISEASE; INFLAMMATION; INTERNEURON; NITROSATIVE STRESS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATERNAL AGE; SEASONAL VARIATION; SUPPLEMENTATION; VITAMIN D DEFICIENCY;

ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE PROGRESSION; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84903534875     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414533012     Document Type: Review

References (219)

1. Abdolmaleky HM, Yaqubi S, Papageorgis P, et al. (2011) Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophrenia Research 129: 183-190.
2. Agartz I, Sedvall GC, Terenius L, et al. (2006) BDNF gene variants and brain morphology in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B: 513-523.
3. Akhondzadeh S, Tabatabaee M, Amini H, et al. (2007) Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90: 179-185.
4. Amminger GP, Schafer MR, Klier CM, et al. (2012) Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Molecular Psychiatry 17: 1150-1152.
5. Amminger GP, Schafer MR, Papageorgiou K, et al. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Archives of General Psychiatry 67: 146-154.
6. Anderson G and Maes M (2013) Schizophrenia: Linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 42: 5-19.
7. Anderson G, Berk M, Dodd S, et al. (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 42: 1-4.
8. Andreasen NC, Nopoulos P, Magnotta V, et al. (2011) Progressive brain change in schizophrenia: A prospective longitudinal study of firstepisode schizophrenia. Biological Psychiatry 70: 672-679.
9. Banerjee J, Alkondon M, Pereira EF, et al. (2012) Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. Journal of Pharmacology and Experimental Therapeutics 341: 500-509.
10. Baptista T and Beaulieu S (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Canadian Journal of Psychiatry 47: 742-749.
11. Barrientos A, Marin C, Miro O, et al. (1998) Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. Journal of Neuroscience Research 53: 475-481.
12. Bauzo RM, Kimmel HL and Howell LL (2012) The cystine-glutamate transporter enhancer N-acetyl-l-cysteine attenuates cocaine-induced changes in striatal dopamine but not self-administration in squirrel monkeys. Pharmacology Biochemistry and Behaviour 101: 288-296.
13. Beard JL, Felt B, Schallert T, et al. (2006) Moderate iron deficiency in infancy: Biology and behavior in young rats. Behavourial Brain Research 170: 224-232.
14. Belforte JE, Zsiros V, Sklar ER, et al. (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neuroscience 13: 76-83.
15. Benes FM, Lim B, Matzilevich D, et al. (2007) Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proceedings of the National Academy of Sciences of the United States of America 104: 10,164-10,169.
16. Ben-Shachar D (2002) Mitochondrial dysfunction in schizophrenia: A possible linkage to dopamine. Journal of Neurochemistry 83: 1241-1251.
17. Bentsen H, Solberg DK, Refsum H, et al. (2012) Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins, Leukotrienes & Essential Fatty Acids 87: 35-41.
18. Berk M, Copolov D, Dean O, et al. (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebo-controlled trial. Biological Psychiatry 64: 361-368.
19. Berk M, Kapczinski F, Andreazza AC, et al. (2011a) Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews 35: 804-817.
20. Berk M, Munib A, Dean O, et al. (2011b) Qualitative methods in earlyphase drug trials: Broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. Journal of Clinical Psychiatry 72: 909-913.
21. Bernstein HG, Keilhoff G, Steiner J, et al. (2011) Nitric oxide and schizophrenia: Present knowledge and emerging concepts of therapy. CNS & Neurological Disorders-Drug Targets 10: 792-807.
22. Bitanihirwe BK and Woo TU (2011) Oxidative stress in schizophrenia: An integrated approach. Neuroscience & Biobehavioral Reviews 35: 878-893.
23. Bocchio Chiavetto L, Boin F, Zanardini R, et al. (2002) Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry 51: 480-484.
24. Boksa P (2010) Effects of prenatal infection on brain development and behavior: A review of findings from animal models. Brain, Behavior, and Immunity 24: 881-897.
25. Bray NJ, Leweke FM, Kapur S, et al. (2010) The neurobiology of schizophrenia: New leads and avenues for treatment. Current Opinion in Neurobiology 20: 810-815.
26. Breese CR, Lee MJ, Adams CE, et al. (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
27. Brown AS, Hooton J, Schaefer CA, et al. (2004) Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. American Journal of Psychiatry 161: 889-895.
28. Browning JL, Patel T, Brandt PC, et al. (2005) Clozapine and the mitogenactivated protein kinase signal transduction pathway: Implications for antipsychotic actions. Biological Psychiatry 57: 617-623.
29. Bruneau EG, McCullumsmith RE, Haroutunian V, et al. (2005) Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophrenia Research 75: 27-34.
30. Burbaeva G, Boksha IS, Tereshkina EB, et al. (2006) Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. The World Journal of Biological Psychiatry 7: 75-81.
31. Cabungcal JH, Steullet P, Kraftsik R, et al. (2013) Early-life insults impair parvalbumin interneurons via oxidative stress: Reversal by N-acetylcysteine. Biological Psychiatry 73: 574-582.
32. Cannon TD, van Erp TG, Rosso IM, et al. (2002) Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Archives of General Psychiatry 59: 35-41.
33. Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 (Suppl 1): S10-14.
34. Carlsson A, Waters N, Holm-Waters S, et al. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annual Review of Pharmacology and Toxicology 41: 237-260.
35. Carmeli C, Knyazeva MG, Cuenod M, et al. (2012) Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: A double-blind, randomized, placebo-controlled trial. PLoS One 7: e29341.
36. Carrizo E, Fernandez V, Quintero J, et al. (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophrenia Research 103: 83-93.
37. Carter CJ (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and longterm potentiation, oxidative stress and oligodendrocyte viability. Schizophrenia Research 86: 1-14.
38. Catts VS, Catts SV, Jablensky A, et al. (2012) Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia. The World Journal of Biological Psychiatry 13: 114-125.
39. Cavelier L, Jazin EE, Eriksson I, et al. (1995) Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29: 217-224.
40. Chakos MH, Lieberman JA, Bilder RM, et al. (1994) Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry 151: 1430-1436.
41. Chan RC, Di X, McAlonan GM, et al. (2011) Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: An activation likelihood estimation meta-analysis of illness progression. Schizophrenia Bulletin 37: 177-188.
42. Charych EI, Liu F, Moss SJ, et al. (2009) GABA(A) receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 57: 481-495.
43. Chaudhry IB, Hallak J, Husain N, et al. (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology 26: 1185-1193.
44. Chittiprol S, Venkatasubramanian G, Neelakantachar N, et al. (2010) Oxidative stress and neopterin abnormalities in schizophrenia: A longitudinal study. Journal of Psychiatric Research 44: 310-313.
45. Choi YB and Lipton SA (2000) Redox modulation of the NMDA receptor. Cellular and Molecular Life Sciences 57: 1535-1541.
46. Clay HB, Sillivan S and Konradi C (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. International Journal of Developmental Neuroscience 29: 311-324.
47. Cobia DJ, Smith MJ, Wang L, et al. (2012) Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophrenia Research 139: 1-6.
48. Colibazzi T, Wexler BE, Bansal R, et al. (2013) Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. PLoS One 8: e55783.
49. Cotter D and Pariante CM (2002) Stress and the progression of the developmental hypothesis of schizophrenia. British Journal of Psychiatry 181: 363-365.
50. Cui K, Luo X, Xu K, et al. (2004) Role of oxidative stress in neurodegeneration: Recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28: 771-799.
51. Curley AA, Eggan SM, Lazarus MS, et al. (2013) Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia. Neurobiology of Disease 50: 179-186.
52. Dammann O and Leviton A (1997) Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatric Research 42: 1-8.
53. Dazzan P, Morgan KD, Orr K, et al. (2005) Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: The AESOP study. Neuropsychopharmacology 30: 765-774.
54. Dean OM, Data-Franco J, Giorlando F, et al. (2012) Minocycline: Therapeutic potential in psychiatry. CNS Drugs 26: 391-401.
55. Dean OM, van den Buuse M, Berk M, et al. (2011) N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. Neuroscience Letters 499: 149-153.
56. Dempster EL, Pidsley R, Schalkwyk LC, et al. (2011) Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Human Molecular Genetics 20: 4786-4796.
57. De Oliveira L, Fraga DB, De Luca RD, et al. (2011) Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metabolic Brain Disease 26: 69-77.
58. Detich N, Bovenzi V and Szyf M (2003) Valproate induces replicationindependent active DNA demethylation. Journal of Biological Chemistry 278: 27,586-27,592.
59. Dietrich-Muszalska A and Olas B (2009) Isoprostenes as indicators of oxidative stress in schizophrenia. The World Journal of Biological Psychiatry 10: 27-33.
60. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. (2000) Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 12: 3721-3728.
61. Dodd S, Maes M, Anderson G, et al. (2013) Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 42: 135-145.
62. Dong E, Agis-Balboa RC, Simonini MV, et al. (2005) Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 102: 12,578-12,583.
63. Dresner E, Agam G and Gozes I (2011) Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. European Neuropsychopharmacology 21: 355-361.
64. Drexhage RC, Hoogenboezem TA, Cohen D, et al. (2011) An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro-and anti-inflammatory forces. The International Journal of Neuropsychopharmacology 14: 746-755.
65. Eack SM, Hogarty GE, Cho RY, et al. (2010) Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: Results from a 2-year randomized controlled trial. Archives of General Psychiatry 67: 674-682.
66. Eide MG, Moster D, Irgens LM, et al. (2013) Degree of fetal growth restriction associated with schizophrenia risk in a national cohort. Psychological Medicine 43: 2057-2066.
67. Ellison-Wright I, Glahn DC, Laird AR, et al. (2008) The anatomy of first-episode and chronic schizophrenia: An anatomical likelihood estimation meta-analysis. American Journal of Psychiatry 165: 1015-1023.
68. Ellman LM, Deicken RF, Vinogradov S, et al. (2010) Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophrenia Research 121: 46-54.
69. Emsley R, Chiliza B, Asmal L, et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13: 50.
70. Ferrari G, Yan CY and Greene LA (1995) N-acetylcysteine (d-and l-stereoisomers) prevents apoptotic death of neuronal cells. The Journal of Neuroscience 15: 2857-2866.
71. Filiou MD, Teplytska L, Otte DM, et al. (2012) Myelination and oxidative stress alterations in the cerebellum of the G72/G30 transgenic schizophrenia mouse model. Journal of Psychiatric Research 46: 1359-1365.
72. Garcia-Cazorla A, Duarte S, Serrano M, et al. (2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8: 273-278.
73. Garver DL, Tamas RL and Holcomb JA (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28: 1515-1520.
74. Gavin DP and Akbarian S (2012) Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiology of Disease 46: 255-262.
75. Gavin DP and Sharma RP (2009) Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia. Cardiovascular Psychiatry and Neurology 2009: 409562.
76. Glausier JR and Lewis DA (2013) Dendritic spine pathology in schizophrenia. Neuroscience 251: 90-107.
77. Goff DC (2013) Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia. World Psychiatry 12: 99-107.
78. Goto N, Yoshimura R, Kakeda S, et al. (2012) Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatric Disease and Treatment 8: 119-122.
79. Grima G, Benz B, Parpura V, et al. (2003) Dopamine-induced oxidative stress in neurons with glutathione deficit: Implication for schizophrenia. Schizophrenia Research 62: 213-224.
80. Guidotti A, Auta J, Chen Y, et al. (2011) Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60: 1007-1016.
81. Guillou H, Martin PG and Pineau T (2008) Transcriptional regulation of hepatic fatty acid metabolism. Subcellular Biochemistry 49: 3-47.
82. Gulyas AI, Megias M, Emri Z, et al. (1999) Total number and ratio of excitatory and inhibitory synapses converging onto single interneurons of different types in the CA1 area of the rat hippocampus. The Journal of Neuroscience 19: 10,082-10,097.
83. Gysin R, Kraftsik R, Sandell J, et al. (2007) Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 104: 16,621-16,626.
84. Harvey BH, Joubert C, du Preez JL, et al. (2008) Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochemical Research 33: 508-517.
85. Hikida T, Jaaro-Peled H, Seshadri S, et al. (2007) Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proceedings of the National Academy of Sciences of the United States of America 104: 14,501-14,506.
86. Ho BC, Andreasen NC, Nopoulos P, et al. (2003) Progressive structural brain abnormalities and their relationship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 60: 585-594.
87. Howes OD and Kapur S (2009) The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophrenia Bulletin 35: 549-562.
88. Howes OD, Kambeitz J, Kim E, et al. (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry 69: 776-786.
89. Hu X, Zhou H, Zhang D, et al. (2012) Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. Journal of Neuroimmune Pharmacology 7: 187-201.
90. Huang HS, Matevossian A, Whittle C, et al. (2007) Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. The Journal of Neuroscience 27: 11,254-11,262.
91. Hulshoff Pol HE, Schnack HG, Mandl RC, et al. (2001) Focal gray matter density changes in schizophrenia. Archives of General Psychiatry 58: 1118-1125.
92. Hulshoff Pol HE, Schnack HG, Mandl RC, et al. (2004) Focal white matter density changes in schizophrenia: Reduced inter-hemispheric connectivity. NeuroImage 21: 27-35.
93. Iwamoto K and Kato T (2009) Epigenetic profiling in schizophrenia and major mental disorders. Neuropsychobiology 60: 5-11.
94. Iwashiro N, Suga M, Takano Y, et al. (2012) Localized gray matter volume reductions in the pars triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and first episode for schizophrenia. Schizophrenia Research 137: 124-131.
95. Javitt DC, Buchanan RW, Keefe RS, et al. (2012) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research 136: 25-31.
96. Joy CB, Mumby-Croft R and Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews (3): CD001257.
97. Jung WH, Jang JH, Shin NY, et al. (2012) Regional brain atrophy and functional disconnection in Broca's area in individuals at ultra-high risk for psychosis and schizophrenia. PLoS One 7: e51975.
98. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27: 1081-1090.
99. Karry R, Klein E and Ben Shachar D (2004) Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. Biological Psychiatry 55: 676-684.
100. Kegeles LS, Mao X, Stanford AD, et al. (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Archives of General Psychiatry 69: 449-459.
101. Kelly DL, Vyas G, Richardson CM, et al. (2011) Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophrenia Research 133: 257-258.
102. Kempf L, Nicodemus KK, Kolachana B, et al. (2008) Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genetics 4: e1000252.
103. Kerksick C and Willoughby D (2005) The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. Journal of the International Society of Sports Nutrition 2: 38-44.
104. Kim HK and Andreazza AC (2012) The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder. Expert Review of Neurotherapeutics 12: 849-859.
105. Krebs M, Leopold K, Hinzpeter A, et al. (2006) Neuroprotective agents in schizophrenia and affective disorders. Expert Opinion on Pharmacotherapy 7: 837-848.
106. Kvajo M, Dhilla A, Swor DE, et al. (2008) Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Molecular Psychiatry 13: 685-696.
107. Kwik-Uribe CL, Gietzen D, German JB, et al. (2000) Chronic marginal iron intakes during early development in mice result in persistent changes in dopamine metabolism and myelin composition. Journal of Nutrition 130: 2821-2830.
108. Laan W, Grobbee DE, Selten JP, et al. (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 71: 520-527.
109. Lam M, Collinson SL, Sim K, et al. (2012) Asymmetry of lexico-semantic processing in schizophrenia changes with disease progression. Schizophrenia Research 134: 125-130.
110. Lavoie S, Murray MM, Deppen P, et al. (2008) Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33: 2187-2199.
111. Lee MA and Meltzer HY (2001) 5-HT(1A) receptor dysfunction in female patients with schizophrenia. Biological Psychiatry 50: 758-766.
112. Leonard BE, Schwarz M and Myint AM (2012) The metabolic syndrome in schizophrenia: Is inflammation a contributing cause? Journal of Psychopharmacology 26: 33-41.
113. Levkovitz Y, Levi U, Braw Y, et al. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Research 1154: 154-162.
114. Lewis DA (2012) Cortical circuit dysfunction and cognitive deficits in schizophrenia-Implications for preemptive interventions. European Journal of Neuroscience 35: 1871-1878.
115. Lewis DA, Fish KN, Arion D, et al. (2011) Perisomatic inhibition and cortical circuit dysfunction in schizophrenia. Current Opinion in Neurobiology 21: 866-872.
116. Lewis DA, Volk DW and Hashimoto T (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: A novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174: 143-150.
117. Lim KO, Tew W, Kushner M, et al. (1996) Cortical gray matter volume deficit in patients with first-episode schizophrenia. American Journal of Psychiatry 153: 1548-1553.
118. Lisman JE, Coyle JT, Green RW, et al. (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neuroscience 31: 234-242.
119. McAllister CG, van Kammen DP, Rehn TJ, et al. (1995) Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. American Journal of Psychiatry 152: 1291-1297.
120. Maes M, Bocchio Chiavetto L, Bignotti S, et al. (2002) Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophrenia Research 54: 281-291.
121. Maes M, Bosmans E, Calabrese J, et al. (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 29: 141-152.
122. Maes M, Bosmans E, Kenis G, et al. (1997a) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research 26: 221-225.
123. Maes M, Bosmans E, Ranjan R, et al. (1996) Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs. Schizophrenia Research 21: 39-50.
124. Maes M, Delange J, Ranjan R, et al. (1997b) Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Research 66: 1-11.
125. Maes M, Meltzer HY and Bosmans E (1994) Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89: 346-351.
126. Maes M, Meltzer HY, Buckley P, et al. (1995b) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. European Archives of Psychiatry and Clinical Neuroscience 244: 325-329.
127. Marchbanks RM, Ryan M, Day IN, et al. (2003) A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophrenia Research 65: 33-38.
128. Matrisciano F, Tueting P, Dalal I, et al. (2013) Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 68: 184-194.
129. Maurer I and Moller HJ (1997) Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Molecular and Cellular Biochemistry 174: 255-259.
130. Mayer M and Noble M (1994) N-acetyl-l-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proceedings of the National Academy of Sciences of the United States of America 91: 7496-7500.
131. Mayilyan KR, Arnold JN, Presanis JS, et al. (2006) Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neuroscience Letters 404: 336-341.
132. Melamed Y, Sirota P, Dicker DR, et al. (1998) Superoxide anion production by neutrophils derived from peripheral blood of schizophrenic patients. Psychiatry Research 77: 29-34.
133. Melas PA, Rogdaki M, Osby U, et al. (2012) Epigenetic aberrations in leukocytes of patients with schizophrenia: Association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB Journal 26: 2712-2718.
134. Meyer U and Feldon J (2012) To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 62: 1308-1321.
135. Miller BJ, Buckley P, Seabolt W, et al. (2011) Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry 70: 663-671.
136. Miller BJ, Culpepper N, Rapaport MH, et al. (2013a) Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry 42: 92-100.
137. Miller BJ, Gassama B, Sebastian D, et al. (2013b) Meta-analysis of lymphocytes in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry 73: 993-999.
138. Mittal VA, Neumann C, Saczawa M, et al. (2008) Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia. Archives of General Psychiatry 65: 165-171.
139. Miyake N, Skinbjerg M, Easwaramoorthy B, et al. (2011) Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biological Psychiatry 69: 822-824.
140. Moller M, Du Preez JL, Emsley R, et al. (2011) Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. European Neuropsychopharmacology 21: 471-483.
141. Moller M, Du Preez JL, Emsley R, et al. (2012) Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by subchronic clozapine treatment. Neuropharmacology 62: 2499-2506.
142. Moller M, Du Preez JL, Viljoen FP, et al. (2013) Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain, Behavior, and Immunity 30: 156-167.
143. Moosmang S, Haider N, Klugbauer N, et al. (2005) Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. The Journal of Neuroscience 25: 9883-9892.
144. Morera AL, Intxausti A and Abreu-Gonzalez P (2009) Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research. The World Journal of Biological Psychiatry 10: 576-580.
145. Moylan S, Maes M, Wray NR, et al. (2013) The neuroprogressive nature of major depressive disorder: Pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry 18: 595-606.
146. Muller N (2008) Inflammation and the glutamate system in schizophrenia: Implications for therapeutic targets and drug development. Expert Opinion on Therapeutic Targets 12: 1497-1507.
147. Muller N, Krause D, Dehning S, et al. (2010) Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research 121: 118-124.
148. Muller N, Riedel M, Scheppach C, et al. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159: 1029-1034.
149. Myint AM, Schwarz MJ, Verkerk R, et al. (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain, Behavior, and Immunity 25: 1576-1581.
150. Na KS, Kim WH, Jung HY, et al. (2012) Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 39: 295-300.
151. Naudin J, Mege JL, Azorin JM, et al. (1996) Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research 20: 269-273.
152. Neddens J, Fish KN, Tricoire L, et al. (2011) Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: Implications for schizophrenia. Biological Psychiatry 70: 636-645.
153. Nel A and Harvey BH (2003) Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine. Behavioral Pharmacology 14: 251-255.
154. Nicodemus KK, Marenco S, Batten AJ, et al. (2008) Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Molecular Psychiatry 13: 873-877.
155. Olabi B, Ellison-Wright I, McIntosh AM, et al. (2011) Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 70: 88-96.
156. Ozawa K, Hashimoto K, Kishimoto T, et al. (2006) Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia. Biological Psychiatry 59: 546-554.
157. Parsons CG, Danysz W, Quack G, et al. (1997) Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: Electrophysiological, biochemical and behavioral characterization. Journal of Pharmacology and Experimental Therapeutics 283: 1264-1275.
158. Passos Gregorio S, Gattaz WF, Tavares H, et al. (2006) Analysis of coding-polymorphisms in NOTCH-related genes reveals NUMBL polyglutamine repeat to be associated with schizophrenia in Brazilian and Danish subjects. Schizophrenia Research 88: 275-282.
159. Pedrini M, Massuda R, Fries GR, et al. (2012) Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research 46: 819-824.
160. Pellmar T (1986) Electrophysiological correlates of peroxide damage in guinea pig hippocampus in vitro. Brain Research 364: 377-381.
161. Perlstein WM, Carter CS, Noll DC, et al. (2001) Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. American Journal of Psychiatry 158: 1105-1113.
162. Petronis A (2004) The origin of schizophrenia: Genetic thesis, epigenetic antithesis, and resolving synthesis. Biological Psychiatry 55: 965-970.
163. Potvin S, Stip E, Sepehry AA, et al. (2008) Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biological Psychiatry 63: 801-808.
164. Powell SB, Sejnowski TJ and Behrens MM (2012) Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin- interneuron maturation in rodent models of schizophrenia. Neuropharmacology 62: 1322-1331.
165. Prabakaran S, Swatton JE, Ryan MM, et al. (2004) Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 9: 684-697, 643.
166. Prabakaran S, Wengenroth M, Lockstone HE, et al. (2007) 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. Journal of Proteome Research 6: 141-149.
167. Prince JA, Yassin MS and Oreland L (1997) Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. Journal of Pharmacology and Experimental Therapeutics 280: 261-267.
168. Rafalowska U, Liu GJ and Floyd RA (1989) Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid. Free Radical Biology & Medicine 6: 485-492.
169. Regenold WT, Phatak P, Marano CM, et al. (2009) Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: Implications for the mitochondrial dysfunction hypothesis. Biological Psychiatry 65: 489-494.
170. Ruzicka WB, Zhubi A, Veldic M, et al. (2007) Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Molecular Psychiatry 12: 385-397.
171. Saetre P, Emilsson L, Axelsson E, et al. (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7: 46.
172. Sandhir R, Sood A, Mehrotra A, et al. (2012) N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease. Neurodegenerative Diseases 9: 145-157.
173. Sapolsky RM (2003) Stress and plasticity in the limbic system. Neurochemical Research 28: 1735-1742.
174. Schiavone S, Jaquet V, Sorce S, et al. (2012) NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology. Translational Psychiatry 2: e111.
175. Schiavone S, Sorce S, Dubois-Dauphin M, et al. (2009) Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biological Psychiatry 66: 384-392.
176. Schizophrenia Psychiatric Genome-Wide Association Study Consortium (2011) Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 43: 969-976.
177. Schobel SA, Chaudhury NH, Khan UA, et al. (2013) Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 78: 81-93.
178. Schwarcz R, Rassoulpour A, Wu HQ, et al. (2001) Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 50: 521-530.
179. Schwartz RD, Skolnick P and Paul SM (1988) Regulation of gammaaminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: Possible role of oxygen radicals. Journal of Neurochemistry 50: 565-571.
180. Schwarz MJ, Muller N, Riedel M, et al. (2001) The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 56: 483-486.
181. Schwarz MJ, Riedel M, Ackenheil M, et al. (2000) Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biological Psychiatry 47: 29-33.
182. Schwieler L, Engberg G and Erhardt S (2004) Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52: 114-122.
183. Selemon LD, Rajkowska G and Goldman-Rakic PS (1995) Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Archives of General Psychiatry 52: 805-818; discussion 819-820.
184. Shergill SS, Cameron LA, Brammer MJ, et al. (2001) Modality specific neural correlates of auditory and somatic hallucinations. Journal of Neurology, Neurosurgery, and Psychiatry 71: 688-690.
185. Shintani F, Kanba S, Maruo N, et al. (1991) Serum interleukin-6 in schizophrenic patients. Life Sciences 49: 661-664.
186. Singh OP, Chakraborty I, Dasgupta A, et al. (2008) A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian Journal of Psychiatry 50: 171-176.
187. Sivrioglu EY, Kirli S, Sipahioglu D, et al. (2007) The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31: 1493-1499.
188. Song C, Lin A, Kenis G, et al. (2000) Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist. Schizophrenia Research 42: 157-164.
189. Sorce S, Schiavone S, Tucci P, et al. (2010) The NADPH oxidase NOX2 controls glutamate release: A novel mechanism involved in psychosis-like ketamine responses. The Journal of Neuroscience 30: 11,317-11,325.
190. Soumiya H, Fukumitsu H and Furukawa S (2011) Prenatal immune challenge compromises development of upper-layer but not deeperlayer neurons of the mouse cerebral cortex. Journal of Neuroscience Research 89: 1342-1350.
191. Sugino H, Futamura T, Mitsumoto Y, et al. (2009) Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 33: 303-307.
192. Sullivan EM and O'Donnell P (2012) Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophrenia Bulletin 38: 373-376.
193. Szeszko PR, Lipsky R, Mentschel C, et al. (2005) Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Molecular Psychiatry 10: 631-636.
194. Talbot K, Eidem WL, Tinsley CL, et al. (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. The Journal of Clinical Investigation 113: 1353-1363.
195. Thakore JH (2004) Metabolic disturbance in first-episode schizophrenia. British Journal of Psychiatry Supplement 47: S76-79.
196. Theberge J, Al-Semaan Y, Williamson PC, et al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. American Journal of Psychiatry 160: 2231-2233.
197. Tohmi M, Tsuda N, Zheng Y, et al. (2007) The cellular and behavioral consequences of interleukin-1 alpha penetration through the blood-brain barrier of neonatal rats: A critical period for efficacy. Neuroscience 150: 234-250.
198. Tosic M, Ott J, Barral S, et al. (2006) Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene. American Journal of Human Genetics 79: 586-592.
199. Toua C, Brand L, Moller M, et al. (2010) The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-d-aspartate and D1 receptor binding in rats. Neuroscience 165: 492-499.
200. Tremolizzo L, Carboni G, Ruzicka WB, et al. (2002) An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proceedings of the National Academy of Sciences of the United States of America 99: 17,095-17,100.
201. Tremolizzo L, Doueiri MS, Dong E, et al. (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biological Psychiatry 57: 500-509.
202. Van Haren NE, Cahn W, Hulshoff Pol HE, et al. (2012) The course of brain abnormalities in schizophrenia: Can we slow the progression? Journal of Psychopharmacology 26: 8-14.
203. Van Haren NE, Hulshoff Pol HE, Schnack HG, et al. (2007) Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study. Neuropsychopharmacology 32: 2057-2066.
204. Vik-Mo AO, Ferno J, Skrede S, et al. (2009) Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS-and liver cells. BMC Pharmacology 9: 10.
205. Vita A and de Peri L (2007) Hippocampal and amygdala volume reductions in first-episode schizophrenia. British Journal of Psychiatry 190: 271. (Pubitemid 46384016
206. Volk DW, Matsubara T, Li S, et al. (2012) Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. American Journal of Psychiatry 169: 1082-1091.
207. White T, Ehrlich S, Ho BC, et al. (2013) Spatial characteristics of white matter abnormalities in schizophrenia. Schizophrenia Bulletin 39: 1077-1086.
208. Winter C, Reutiman TJ, Folsom TD, et al. (2008) Dopamine and serotonin levels following prenatal viral infection in mouse-implications for psychiatric disorders such as schizophrenia and autism. European Neuropsychopharmacology 18: 712-716.
209. Wong CT, Tsoi WF and Saha N (1996) Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophrenia Research 22: 165-171.
210. Woo TU, Kim AM and Viscidi E (2008) Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Research 1218: 267-277.
211. Woo TU, Pucak ML, Kye CH, et al. (1997) Peripubertal refinement of the intrinsic and associational circuitry in monkey prefrontal cortex. Neuroscience 80: 1149-1158.
212. Woo TU, Spencer K and McCarley RW (2010) Gamma oscillation deficits and the onset and early progression of schizophrenia. Harvard Review of Psychiatry 18: 173-189.
213. Wood SJ, Yucel M, Pantelis C, et al. (2009) Neurobiology of schizophrenia spectrum disorders: The role of oxidative stress. Annals of the Academy of Medicine, Singapore 38: 396-401.
214. Yacubian J, de Castro CC, Ometto M, et al. (2002) 31P-spectroscopy of frontal lobe in schizophrenia: Alterations in phospholipid and highenergy phosphate metabolism. Schizophrenia Research 58: 117-122.
215. Yang TT and Wang SJ (2008) Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: Possible relevance to neuroprotective interventions in schizophrenia. Synapse 62: 804-818.
216. Yao L, Lui S, Liao Y, et al. (2013) White matter deficits in first episode schizophrenia: An activation likelihood estimation meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry 45: 100-106.
217. Young-Pearse TL, Suth S, Luth ES, et al. (2010) Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. The Journal of Neuroscience 30: 10,431-10,440.
218. Zhang XY, Tan YL, Zhou DF, et al. (2007) Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 32: 2020-2024.
219. Zipursky RB, Reilly TJ and Murray RM (2013) The myth of schizophrenia as a progressive brain disease. Schizophrenia Bulletin 39: 1363-1372.